The Takeovers Panel has agreed to hear Mayne Pharma’s latest dispute with Cosette over the US drug maker’s attempts to walk away from their $672 million merger agreement and extended the timeline for completing the deal.
Mayne Pharma has secured an extension of the deadline for securing Foreign Investment Review Board approval of its $672 million tie-up with US drug maker Cosette.
Cosette plans to appeal a ruling that rejected its bid to terminate an agreement to merge with Mayne Pharma, as the US drug company also refuses to agree to conditions needed to win Foreign Investment Review Board approval for the tie-up.
The applicant in a class action against AMP wants to amend the case five years in and three months out from trial, but a judge has warned he will look dimly on any changes that disrupt the evidence planned for the hearing.
Mayne Pharma has won a dispute with US drug maker Cosette over the termination of a $672 million merger agreement, with a judge finding Mayne did not breach its continuous disclosure obligations by failing to disclose a letter from the US FDA sooner.
Property group Catalyst has won $31.7 million from a trustee corporation of the Presbyterian Church of Queensland over a suite of scuppered transactions for land and aged care homes.
An appeals court has dismissed BlueScope Steel’s challenge to a decision finding it engaged in attempted price-fixing and was on the hook for a record $57.5 million penalty.
TaxiApps, the operator of the GoCatch rideshare app, has failed to prove that Uber engaged in an unlawful conspiracy, despite a judge finding the rideshare giant intended to harm the defunct taxi app and “surreptitiously” obtained a confidential driver list.
Mayne Pharma and US drug maker Cosette have agreed to postpone the start of trial in a case over the termination of a $672 million merger to allow for late amendments.
The High Court has unanimously found the Federal Court has no power to allow solicitors to take a cut of a settlement or judgment in a shareholder class action against Blue Sky, saying it would be contrary to rules against contingency fees in NSW.